MDLN vs RMD stock comparison
Medline vs. Resmed · data as of November 13, 2026
Medline (MDLN) has a market value of about $51.9B, Resmed (RMD) about $33.7B. Over their latest twelve months Medline had revenue of $30.7B and Resmed $5.7B.
On our five checks Resmed scores higher: 4.2 out of 5 (excellent) against 1.0 (weak).
By area, the stronger company is Resmed on value; Resmed on future growth; Resmed on track record; Resmed on financial health; Resmed on shareholder returns.
Resmed is cheaper on earnings (P/E 21.8 vs. 89.7).
Medline leads on 4 of the compared lines and Resmed on 18.
Side by side
| MDLN | RMD | |
|---|---|---|
| Size and price | ||
| Market cap | $51.9B | $33.7B |
| Share price | $39.47 | $239.53 |
| Score | ||
| Overall score (of 5) | 1.0 | 4.2 |
| Value | 0 | 3 |
| Future growth | 2 | 4 |
| Track record | 0 | 5 |
| Financial health | 2 | 5 |
| Shareholder returns | 1 | 4 |
| Valuation | ||
| P/E (TTM) | 89.7 | 21.8 |
| Forward P/E | 26.2 | 18.9 |
| Price / free cash flow | 27.4 | 20.9 |
| Price / sales | 1.7 | 5.9 |
| EV / EBITDA | 22.6 | 15.9 |
| PEG | — | 0.83 |
| DCF value vs. price | −48% | −28% |
| Business | ||
| Revenue | $30.7B | $5.7B |
| Net income | $566M | $1.6B |
| Free cash flow | $1.9B | $1.6B |
| Net margin | 1.8% | 27.8% |
| Gross margin (5-yr avg.) | 26.4% | 57.9% |
| ROIC (5-yr avg.) | 8.6% | 18.9% |
| Growth | ||
| Revenue growth (1 yr) | 11.5% | 9.8% |
| Revenue growth (5 yrs, per year) | — | 12.1% |
| EPS growth (5 yrs, per year) | — | 26.3% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$9.1B | $400M |
| Dividend yield | None | 1.10% |
| Shareholder yield | 0.1% | 3.2% |
| Analysts | ||
| Upside to average target | +15% | +10% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: MDLN TTM to September 30, 2026, RMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Medline or Resmed?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Resmed scores 4.2 out of 5 and Medline 1.0; the table shows where each one is stronger.
Is Medline cheaper than Resmed?
On trailing earnings, Resmed trades at a P/E of 21.8 and Medline at 89.7, so Resmed is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which pays a higher dividend?
Medline yields nothing (no dividend) and Resmed 1.10%.
Full Medline analysis → Full Resmed analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.